Our Pipeline

Our programs span discovery-stage to late-stage development and cover a range of high-value indications. We aim to pursue programs we believe could be first-in-class / best-in-class and where there is prior learning in human genetics or precedented human activity for a pathway of interest. We place a premium on learnings from the clinic, whereby a drug has established the relevance of a biological pathway contributing to disease outcome. Our approach is to pursue the best assets in a capital efficient manner and rapidly progress our programs through development, evaluating the unique biological advantage of our product candidates.

View our Expanded Access Policy for investigational medical products.

Phase 1
Phase 2
Phase 3
Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser